Author

Ling Zhang

Institutions: Yuhuangding Hospital, InventisBio Co., Ltd. (China)

Observed institutions: Yuhuangding Hospital, InventisBio Co., Ltd. (China)

ORCID: 0000-0003-0383-461X

Observed ORCID: 0000-0003-0383-461X

OpenAlex ID: A5077150332

Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial

2024 · Ziming Li, Xiaomin Dang, et al. · The Lancet Respiratory Medicine · 57

Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation

2025 · Dan-Yun Ruan, Hao-Xiang Wu, et al. · Signal Transduction and Targeted Therapy · 35

Garsorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: A pooled analysis of phase 1/2 study

2025 · Zhengbo Song, Ziming Li, et al. · European Journal of Cancer · 5

Works count: 3

Citation count: 97

H-index: 3

I10-index: 2